Koninklijke Philips N.V.
NYSE:PHGMedical - Devices
+$0.57 today
- Market cap
- $29.11B
- Beta
- 0.93
- P/E (TTM)
- 23.1
- EPS (TTM)
- $1.02
- Dividend yield
- 3.62%
Volume 1.45M
Average 1.17M
PHG Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Koninklijke Philips N.V.NYSE: PHG
Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026
Capital expenditures dips below year-ago levels
Q2 FY2026 capital expenditures of €157M (cash outflow) fell 1.3% year over year, behind the +76.2% change in trailing-twelve-month capital expenditures. Sequentially, it rose 111.6% from the prior quarter. Over 3 fiscal years it compounded at -16.8% a year.
Context
- Capital expenditures amounted to 1.5% of revenue in FY2025, down 0.4 pp from a year earlier.
- Capital expenditures grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -1.3% toward the trailing-twelve-month pace of +76.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
EUR · from the cash flow
- Latest · FY2025
- (269M) EUR
- Year-over-year change
- +21.6%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (269M) | +21.6% |
| FY2024 | 2024-12-31 | (342.9M) | +7.8% |
| FY2023 | 2023-12-31 | (371.9M) | +20.3% |
| FY2022 | 2022-12-31 | (466.63M) | +0.6% |
| FY2021 | 2021-12-31 | (469.25M) | — |
Capital Expenditures vs competitors
How PHG compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +76.2% is the 3rd highest of 10, against a peer median of +13.6%.
- Capital expenditures amounts to 2.2% of revenue for PHG, versus a peer median of 4.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $1.9B USD | +3.3% | +9.3% | 5.1% | |
| LTM Jun 2026 | $1.19B USD | -47.6% | +6.9% | 2.5% | |
| LTM Jun 2026 | $904M USD | -7.2% | +12.7% | 4.3% | |
| LTM Jun 2026 | $522M USD | +21.4% | +15.8% | 2.6% | |
| FY2025 | $433M USD | +13.6% | +6.5% | 7.0% | |
| LTM Jun 2026 | €382.2M EUR | +76.2% | -16.8% | 2.2% | |
| LTM Jun 2026 | $267.46M USD | +188.0% | +5.3% | 4.7% | |
| LTM Sep 2026 | $108.84M USD | +83.8% | +45.2% | 7.2% | |
| LTM Mar 2026 | $4.85M USD | -59.7% | +60.6% | 5.6% | |
| LTM Mar 2026 | $412K USD | +72.4% | -18.0% | 0.4% | |
| Peer median (excluding PHG) | — | +13.6% | +9.3% | 4.7% | |
Competitors are the stored peer set for PHG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 718.64M | (1.7B) | (492.99M) | (912.95M) | 895M |
| Depreciation & Amortization | 1.32B | 1.6B | 1.26B | 1.39B | 1.13B |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 141M |
| Change in Working Capital | (179.66M) | (1.24B) | 1.51B | 7.57M | (1.33B) |
| Accounts Receivables | 0 | (359.43M) | 322.17M | (1.08M) | (9M) |
| Inventory | (686.73M) | (601.16M) | 277.85M | 248.79M | (115M) |
| Accounts Payables | 258.85M | 54.65M | 387.04M | (630.63M) | 0 |
| Other Working Capital | 248.22M | (337.36M) | 518.94M | 390.49M | (1.21B) |
| Other Non-Cash Items | 64.65M | 1.16B | 35.26M | 1.21B | 330M |
| Operating Cash Flow | 1.93B | (181.82M) | 2.31B | 1.7B | 1.16B |
| Capital Expenditures | (469.25M) | (466.63M) | (371.9M) | (342.9M) | (269M) |
| Acquisitions (Net) | (3.5B) | (600.11M) | 104.87M | 141.7M | (3M) |
| Purchases of Investments | (146.57M) | (197.58M) | (149.19M) | (133.05M) | 0 |
| Sales of Investments | 203.3M | 81.98M | 51.89M | 61.66M | 0 |
| Other Investing Activities | 4.02B | (12.61M) | 134.06M | 27.04M | (465M) |
| Investing Cash Flow | (317.95M) | (1.58B) | (553.53M) | (633.87M) | (737M) |
| Debt Repayment | (296.68M) | 1.15B | (195.68M) | (88.7M) | 448M |
| Common Stock Issued | 27.19M | 12.61M | 0 | 0 | 0 |
| Common Stock Repurchased | (1.93B) | (196.53M) | (715.7M) | (444.57M) | 0 |
| Dividends Paid | (569.71M) | (433M) | (2.16M) | (1.08M) | (328M) |
| Other Financing Activities | (2.36M) | (6.31M) | (3.24M) | (2.16M) | (13M) |
| Financing Cash Flow | (2.77B) | 525.49M | (916.79M) | (536.52M) | 107M |
| Effect of Forex Changes | (162.77M) | (136.41M) | (25.17M) | (105.14M) | (139M) |
| Net Change in Cash | (1.33B) | (1.37B) | 813.77M | 421.64M | 393M |
| Free Cash Flow | 1.46B | (648.45M) | 1.94B | 1.35B | 893M |
Koninklijke Philips N.V.
NYSE:PHG
Intrinsic Alpha fair value
Locked
Current Price
$29.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.